Mike Druckman

ID: 1b837770-2619-30fb-68c4

/

Unclaimed

/

Organization: Hogan Lovells

FDA Shows that it Means Business in Stopping Stem Cell Clinics that Put Patients at Risk

Focus on Regulation · May 11, 2018

FDA Shows that it Means Business in Stopping Stem Cell Clinics that Put Patients at Risk

Focus on Regulation · May 11, 2018

The Crackdown Continues: FDA Takes Action Against Company And Its Autologous Stem Cell Product, Alleging Significant Safety Concerns

Focus on Regulation · January 5, 2018

New Legislation Increases Access to Medical Products for Military Applications

Focus on Regulation · December 12, 2017

FDA Clarifies and Expands Eligibility for RMAT Designation for Gene Therapies

Focus on Regulation · November 22, 2017